# 此超級綜合評級是基於以下評級的加權平均結果。

*biotech · news · 2026-05-28 · MarketScreener*

## Key points

- Trader 超級評級強調較短期的每股盈餘（EPS）修正，聚焦過去四個月。
- Investor 超級評級使用全年 EPS 修正，針對較長期趨勢。
- 全球評級要求公司必須被五個特定因素中的至少四個涵蓋。
- 品質評級需要至少三個因素中的兩個，包括財務健康和報告品質。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/zydus-lifesciences-says-us-fda-grants-priority-review-to-zydus-therapeutics-nda-for-saroglitazar-to-ce7f5ddadd8af520)

---

Canonical: https://newsio.io/zh-TW/n/978845c9-e2aa-4739-81f8-76b4577c765b/
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works